Introduction
Mycophenolic acid (MPA), the immunosuppressive metabolite of prodrug mycophenolate mofetil (MMF), is a potent, selective, reversible, and uncompetitive inhibitor of inosine monophosphate dehydrogenase in the de novo purine synthesis1). It has been reported that MMF reduces the frequency of acute rejection in renal transplant recipients when administered together with calcineurin inhibitors and corticosteroids2-4). MPA is primarily metabolized by glucuronosyl transferase to the phenolic glucuronide of MPA (MPAG) , which is pharmacologically inactive. The pharmacokinetics of MPA has great interpatient variability in transplant recipients5-7). MPAG is hydrolyzed back to MPA during enterohepatic circulation ; therefore the second peak in MPA concentration is observed 6-12 h following oral administration of MMF6 r2, the coefficients of determination; ME%, mean prediction error (%); MAE%, mean absolute prediction error (%); RMSE%, root mean squared error (%) was about 30% (vs. 22.6% for the combination of Co, C3 and C8) ( Table 5 ). The MPA pharmacokinetics, especially in the parameters of absorption phase, had a substantial variability (Table 3 , Fig.1 ). On the other hand, pre-dose concentration has less variability and frequently monitored at clinical routine sampling in TAC-based immunosuppression. Accordingly, the equation with three-point analysis containing C0, C3 and C8 is much preferable for estimating AUC of MPA. This strategy requires a final sampling at 8 hours after dosing, which might be inconvenient for recipients. Therefore, the pre-dose concentration of MPA should be mainly monitored in a routine like in TAC therapy, and this threepoint analysis must be applied to patients with critical situations such as early period after transplantation, changing gastrointestinal absorption dramatically, or suspecting toxicity or underimmunosuppression.
In the estimation of AUC of MPA by this equation, AUC does not increase proportionally with increasing each concentration because the equation has a constant. However, since there is a linearity between AUC of MPA and dose of MMF9), the effect of the constant on the estimation of AUC must be smaller and smaller according to increasing AUC. Therefore, the equation derived from our study could be applied widely to many cases in clinical settings. In the future, to confirm the applicability, we would like to evaluate the AUC predictability using this equation in other group including higher AUC.
